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Introduction
The addition of the anti-CD20 antibody rituximab (R) to chemotherapy improved the survival of patients with aggressive B-cell lymphomas of all ages and prognostic subgroups [1] [2] [3] . Nonetheless, about one-third of patients experience progression during or relapse after first-line therapy. For younger patients both the CORAL trial [4] and the NCIC CGT study LY12 [5] reported results of salvage therapy followed by high-dose therapy and autologous stem-cell transplantation (HDT/ASCT). We reported promising data using myeloablative conditioning and allogeneic transplantation (alloSCT) in such patients [6] . Few results of salvage therapy have been published in patients beyond 60 years failing modern immunochemotherapy who in many instances are not candidates for transplantation. Besides clinical risk factors a number of biological markers negatively affecting survival of patients with aggressive B-cell lymphomas have been described. MYC rearrangement [7, 8] as well as immunohistochemistry (IHC) positive for MYC, bcl-2 and negative for bcl-6 alone or in combination (double-or triple-hit lymphomas) [9] [10] [11] have been shown to negatively influence prognosis.
We analysed the impact of the first-line therapy with or without R, time to relapse, type of salvage therapy (chemotherapy, high-dose therapy, radiotherapy with or without R), and the presence of biological risk factors at diagnosis on the results of second-line treatment in elderly patients who had participated in the RICOVER trial [12] of the German High-Grade Lymphoma Study Group (DSHNHL).
Patients and methods
In the RICOVER trial 1222 patients aged 61-80 years suffering from aggressive B-cell lymphoma received biweekly CHOP with or without standard dose R (375 mg/m 2 ). Patients had been randomized to six or eight courses of CHOP-14 without (n ¼ 612) or with (n ¼ 610) eight infusions of R. Patients with bulky or extranodal disease received 36 Gray involved field radiotherapy. Further details of the study have been reported [12] .
Here we report the results of a retrospective analysis on 297 patients who experienced treatment failure due to progressing, persistent or relapsed lymphoma (TF-L). Salvage therapy was chosen by the individual investigator, detailed information on salvage regimens used, whether they included R and/or HDT/ASCT as well as details of radiotherapy were retrieved from the RICOVER-60 database at the Institute of Medical Informatics, Statistics and Epidemiology, Leipzig, Germany. Response to salvage therapy classified as complete remission (CR), CR unconfirmed (CRu), partial remission (PR), stable disease (SD) or progressive disease (PD) were defined as described previously [12] . Because significant differences between patients treated with six or eight courses of chemotherapy did not emerge all subsequent analyses compare outcomes of patients receiving six or eight cycles of R-CHOP-14 to those of patients given six or eight cycles of CHOP-14.
FISH and immunohistochemistry
MYC translocations were detected by fluorescence in situ hybridisation. MYC, bcl-2 and bcl-6 IHC staining and scoring was done as previously described [10] .
Statistical analysis
Relapse after having achieved a CR/CRu or a diagnosis of PR, SD or PD at the end of protocol treatment or within 2 months after end of therapy were counted as TF-L. Overall survival (OS) after TF-L was defined as time from TF-L until death of any cause. Time to TF-L was defined as time from randomization to TF-L. Observations were censored at the date a patient was last known to be alive. Time-to-event distributions were estimated using the Kaplan-Meier method. Estimators at 2 years are given with 95% confidence intervals (CI). Univariate analyses were done using log-rank tests. Multivariate analyses were carried out using Cox proportional hazard models. For comparison of clinical factors or international prognostic index (IPI) scores for patients treated with or without rituximab v 2 tests or if necessary Fishers's exact tests were carried out.
All tests for significance are at the two-sided 5% significance level. Statistical analyses were done with PASW (version 18.0). The RICOVER-60 trial was registered on the National Cancer Institute website, number NCT0052936 and as EU-20243.
Results
Incidence and characteristics of treatment failures With a median observation time of 26.5 months (range 0.03-61.6 months) after TF-L had occurred, the 2-year OS rate was 31.7% (95% CI: 25.8-37.6), median OS was 9. Survival after TF-L for all relapsed patients showed a trend towards a worse outcome of patients treated with rituximab given frontline (P ¼ 0.107); median survival was 14.2 months after R-CHOP compared with 18.5 months after CHOP; 2-year OS rates were 34.8% and 48.2% [95% CI (18.5-51.1) and (37.0-59.4)], respectively ( Figure 2B ).
Treatment failures according to biological risk factors
The percentage of patients with TF-L was 24.7% in 100 of 405 patients analysed regarding MYC translocations but was 41.7% for 15 of 36 patients positive for MYC translocation. Adjusted for IPI factors MYC-positivity remained a significant prognostic factor for OS after TF-L in all patients [RR ¼ 2.6, 95% CI (1.3-5.1), P ¼ 0.006] and in patients treated with CHOP [RR ¼ 4.8, 95% CI (2.1-11.2), P < 0.001, Figure 1A and B]. There was a significant interaction between having received R as part of first-line therapy and MYC rearrangement (RR ¼ 0. Patients being MYC-positive by IHC experienced TF-L in 31.8% (28 of 88 patients) with similar results found between patients who had received CHOP (16 of 46 patients, 34.8%) or R-CHOP (12 of 42 patients, 28.6%). Cox models comparing patients being MYC IHC-positive to patients being MYC IHCnegative showed results comparable to those reported for MYC rearrangements (data not shown).
OS after TF-L of patients with high bcl-2 or low bcl-6 expression by IHC at diagnosis did not significantly differ (data not shown).
Second-line therapy
Fifty-seven patients (19.2%) did not receive salvage therapy: 20 of 24 patients (83.3%) relapsing after R-CHOP and 23 of 33 (69.7%) patients relapsing after CHOP died. At the time of this analysis, 14 patients (24.6%) were alive at last follow-up. For 16 patients (5.4%) detailed information on salvage therapy was not available, but death was documented for 12 of these patients.
Two hundred and twenty-four patients (75.4%) did receive salvage therapy that consisted of chemotherapy in 88.3% (n ¼ 197, chemotherapy regimens are listed in supplementary  Table S2 , available at Annals of Oncology online), R with or without chemotherapy in 57.4% (n ¼ 128), radiotherapy in 34.1% (n ¼ 76) and HDT/ASCT in 12.6% (n ¼ 28) (supplementary Figure S1 , available at Annals of Oncology online). The response after salvage therapy is documented in supplementary Table S1 , available at Annals of Oncology online. Four additional patients (two without/two with rituximab) with treatment failure were observed within RICOVER-60 trial, but excluded for this analysis due to being under therapy after presenting the study results and EFS and OS were therefore censored within the RICOVER-60 trial.
Primary PD
Salvage therapy was given to 64 of 91 patients (70.3%) with primary PD. Overall response rate was 25.0% (16/64 patients).
Overall response rate was 27.5% (11/40) in patients failing CHOP and 20.8% (5/24) in patients failing R-CHOP. Median OS after PD was 3.3 months with a 2-year OS rate of 10.1% (95% CI: 3.6-16.6). OS did not significantly differ between patients treated with or without R as part of first-line therapy (P ¼ 0.5894) (Figure 2A ).
Early and late relapse
Survival after TF-L was affected by both prior administration of R and time to treatment failure. Figure S3 , available at Annals of Oncology online). Focusing on patients with early relapse OS was significantly worse for patients relapsing after R-CHOP than after CHOP (P ¼ 0.023). For patients with late relapse no significant difference between patients treated with CHOP or R-CHOP was Table S1 , available at Annals of Oncology online). The response rates (44% versus 49%) and the CR/Cru rates (33% versus 40%) were lower after first-line R-CHOP compared with CHOP but these differences were not significant; 47.6% of patients reached a second CR/CRu (59/124); there was no significant difference between patients who had been pretreated with or without R (P ¼ 0.243) (supplementary Table S2 , available at Annals of Oncology online). Of 128 patients (57.4%) receiving R as a part of salvage therapy, 99 patients (77.3%) were R-naive while 29 patients (22.7%) had received R with first-line therapy. Repeated administration of R with salvage therapy resulted in significantly better OS ( Figure  3B ) with 2-year survival rates of 49.6% (95% CI: 38.8-60.4) versus 19.1% (95% CI: 6.9-31.3; P < 0.001) for patients not given R in first line. After first-line therapy with R-CHOP administration of R as part of salvage therapy remained significant resulting in better median OS (15.5 versus 7.4 months, Figure 3A) . Despite its beneficial effect re-exposure to R of patients initially treated with R-CHOP resulted in a 2-year OS rate of only 33.1% (95% CI: 10.8-55.4) compared with 22.5% (95% CI: 10.0-35.0) when R had not been administered (P ¼ 0.034). When R was combined with chemotherapy, HDT or radiotherapy as part of salvage therapy, it improved OS in each of these combinations (data not shown). In a Cox model including HDT, radiotherapy, and R adjusted for R as part of first-line therapy and the factors of the IPI, R as part of salvage therapy remained highly significant [RR ¼ 0.4 (95% CI: 0.3-0.6), P < 0.001].
High-dose therapy
HDT/ASCT was carried out in 28 of these elderly patients (12.6%): 16 patients had received CHOP and 12 patients had received R-CHOP first line. Eighteen patients (64.3%) were transplanted after relapse, 7 patients (25.0%) with PD, and 3 patients with PR after first-line therapy. In univariate analysis, HDT/ASCT compared with other salvage strategies led to significantly better survival (P ¼ 0.035). For patients with TF-L after CHOP, HDT/ASCT resulted in a significant prolongation of survival in univariate analysis (P ¼ 0.014) and a significantly better 2-year OS rate of 65.5% (95% CI: 40. 8 
Discussion
We analysed patients between 61 and 80 years of age with aggressive B-cell lymphoma (mostly DLBCL) who had been treated in a large prospective, randomized trial comparing R-CHOP with CHOP and report on biological and clinical risk factors of 301 patients who were refractory under therapy or relapsed after having achieved a CR.
As expected, the number of treatment failures due to lymphoma was lower after immunochemotherapy than after chemotherapy alone [1, 2] . Once treatment failure had occurred, however, survival was significantly shorter in patients pretreated with R [4] .
MYC translocations and aberrant MYC-expression have been reported to represent adverse prognostic markers independent of clinical risk factors in patients treated with CHOP and R-CHOP [ [7] [8] [9] [10] [11] . We show that R as part of first-line therapy reduced the risk of TF-L for patients with MYC rearrangement from 58.8% to 26.3%. Patients with MYC-break accumulated in the group of patients with TF-L regardless if first-line therapy comprised R or not. For patients with MYC-overexpression by IHC the risk of TF-L was not different between patients treated with (28.6%) or without R (34.8%). This information although based on investigations carried out at diagnosis is clinically important because these biological markers have been reported to be stable during the evolution of aggressive B-cell lymphoma [13] . After treatment failure, MYC-break or MYC expression by IHC was prognostic after CHOP but not after R-CHOP. The same correlation was not detected in patients progressing or relapsing after R-CHOP; however, the number of cases was small and firm conclusions therefore cannot be drawn. The prognostic implications of 'bcl-2 translocations/expression' and 'bcl-6 expression' in patients with DLBCL are controversial [10] . In this elderly population, we were unable to detect significant differences in survival after TF-L for patients being bcl-2 positive or -negative and patients having low expression of bcl-6 or not.
Prognosis of elderly patients with primary PD was particularly poor with all treatment modalities used. A median survival of 3.3 months and long-term disease control in 15% of patients regardless of initial therapy are truly discouraging. Unfortunately, our findings are in line with other reports on salvage therapy in this population [14] .
Among clinical risk factors influencing the prognosis of patients with refractory or relapsed DLBCL time to treatment failure was described to represent an important prognostic factor long time ago [15] . This finding was confirmed in the CORAL study where younger patients receiving R and platinum-based salvage chemotherapy followed by HDT/SCT achieved a disappointing 3-year PFS of 23% when treated for early relapse [4] whilst prognosis after late relapse was significantly better (3-year PFS 45%). We show that outcome of elderly patients treated with or without R also is significantly worse for patients with early when compared with late relapse.
In patients with TF-L after CHOP alone, lasting remissions could be achieved with salvage therapy in a sizeable fraction of patients. In contrast, after R-CHOP given first-line median survival was only 5.5 months after early and 15.5 months after late relapse. Even in the latter group relapses and deaths continued to occur and few if any long-term survivors can be expected. Nonresponders to R-containing first-line chemotherapy rarely respond to conventional salvage therapy. Such patients should be treated on clinical trials investigating new agents or modalities. For selected patients, HDT/ASCT or allogeneic transplantation might offer a curative chance [6] . If none of these options can be pursued, single-agent chemotherapy and best supportive care is the remaining option.
Prognosis of patients who relapse after having achieved a remission is much better than after primary progression. Similar observations have been reported from other cohorts of patients treated with various salvage regimens with and without R [16] [17] [18] .
We also analysed survival after TF-L according to the various therapeutic options chosen by the treating physicians. Best supportive care was given to some patients who had not reached CR or CRu after first-line therapy probably based on the assumption that another remission will rarely be achieved in these elderly patients. This might not always be true; at least in patients below 65 years van de Neste et al. recently showed that another remission can be reached in a significant percentage of such patients if HDT/ASCT is carried out after salvage therapy [19] .
Rituximab is an effective agent also in patients with relapsed lymphoma [16, 17, 20] . Survival after R-containing salvage therapy was better in all patient groups supporting the repeated administration of R to all patients needing salvage therapy.
For more than two decades following publication of only one randomized trial [21] , thousands of younger patients with relapsed aggressive B-cell lymphoma have been treated with salvage chemotherapy followed by HDT. In our cohort of elderly patients, HDT/ASCT was carried out in only few patients but was reasonably effective in 16 patients who had received first-line treatment without R. In contrast, long-term benefit for patients who had been treated with R-CHOP was not achieved. Because alloSCT-a promising option for younger patients [6] -will rarely be feasible in patients beyond 70 years of age novel less toxic strategies are urgently needed.
In conclusion, this analysis of elderly patients with aggressive B-cell lymphoma confirms that relapses after R-CHOP are less frequent than after chemotherapy alone. Rituximab as part of first-line therapy mitigated the negative effects of MYC rearrangements on survival after TF-L; Bcl-2 and bcl-6 expression did not significantly influence treatment outcomes after TF-L. Overall, the outcome of second-line treatment of elderly patients with refractory and relapsed aggressive B-cell lymphoma is disappointing and worse than in younger patients regardless of the modality chosen. New drugs and treatment modalities with the potential to change the dismal outlook for elderly patients with aggressive B-cell lymphomas are eagerly awaited.
